ResearchMoz

Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market

GBI Research
Published Date » 2013-01-04
No. Of Pages » 43
     
  Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market  
   
  Summary  
   
 Leading business intelligence provider GBI Research has released its latest research report, entitled “Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market”. The current opioids market is characterized by a very broad and highly diversified product portfolio. Patients experiencing moderate to severe pain for a range of underlying physiological reasons are virtually exclusively treated with opioid analgesics. As a result, most patient populations experiencing more severe levels of pain across most pain indications, with the...
Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 6
1.2 List of Figures 6

2 Introduction 7
2.1 Introduction 7
2.1.1 High Levels of Product Diversification in a Highly Competitive Market Environment 7
2.1.2 Inconsistent Clinician Prescribing Preferences 7
2.1.3 Ongoing Market Shift Towards Abuse-Resistant Product Formulations 8
2.1.4 Increasingly Vocal Physician Associations Raise Concerns About Extent of Opioid Abuse 9
2.1.5 Full Commercial Potential of Transdermal Patches May Have Yet to be Fully Exploited 9

3 Overview of Currently Marketed Products 10
3.1 Major Marketed Products 10
3.1.1 Oxycontin 10
3.1.2 Exalgo 10
3.1.3 Onsolis 10
3.1.4 Duragesic 11
3.1.5 Opana ER 11
3.1.6 Vicodin CR 11
3.1.7 Dolophine Hydrochloride 11
3.1.8 Oxecta 11
3.1.9 Actiq 12
3.1.10 Embeda 12
3.1.11 Kadian 12
3.1.12 Avinza 12
3.2 Market Drivers and Barriers 13
3.2.1 Drivers 14
3.2.2 Barriers 15

4 Pipeline Analysis 17
4.1 Introduction 17
4.2 Opioid Compounds in the Developmental Pipeline 20
4.3 Distribution by Route of Administration 23
4.4 Promising Pipeline Products 26
4.4.1 ARX-01, AcelRX Pharmaceuticals 26
4.4.2 ALO-02, Pfizer 26
4.4.3 Zohydro ER, Zogenix 26
4.4.4 ELI-216, Elite Pharmaceuticals 27
4.4.5 BEMA Buprenorphine 27
4.4.6 CEP-33237, Cephalon 27

5 Deals Analysis 28
5.1 Overview: 28
5.1.1 M&As by Year 28
5.1.2 M&As by Value 29
5.1.3 Major M&As 30
5.2 Licensing Agreements 33
5.2.1 Licensing Agreements by Year 33
5.2.2 Licensing Agreements by Value 34
5.2.3 Major Licensing Agreements 35
5.3 Co-Development Agreements 38
5.3.1 Deals by Year 38
5.3.2 Major Co-Development Deals 39

6 Appendix 40
6.1 Abbreviations 40
6.2 Bibliography 41
6.3 Research Methodology 41
6.3.1 Coverage 41
6.3.2 Secondary Research 42
6.3.3 Primary Research 42
6.3.4 Pipeline Analysis 42
6.3.5 Expert Panel Validation 42
6.4 Contact Us 43
6.5 Disclaimer 43

List of Tables


Table 1: Opioids Market, Global, R&D Pipeline Analysis by Phase, 2012 18

List of Figures


Figure 1: Opioids Market, Drivers and Barriers, 2012 13
Figure 2: Opioids Market, Global, R&D Pipeline by Phase (%), 2012 17
Figure 3: Opioids Market, Pipeline Analysis,,Opioid Compounds in Phase III 20
Figure 4: Opioids Market, Pipeline Analysis,,Opioid Compounds in Phase II 21
Figure 5: Opioids Market, Pipeline Analysis,,Opioid Compounds in Phase I 22
Figure 6: Opioids Market, Pipeline Analysis, Route of Administration for Pipeline Molecules Currently in Phase III 23
Figure 7: Opioids Market, Pipeline Analysis, Route of Administration for Pipeline Molecules Currently in Phase II 24
Figure 8: Opioids Market, Pipeline Analysis, Route of Administration for Pipeline Molecules Currently in Phase I 25
Figure 9: Opioids Market, M&As by Year, 2005–2012 28
Figure 10: Opioids Market, M&As by Value ($m), 2005–2012 29
Figure 11: Opioids Market, Licensing Agreements by Year, 2005–2012 33
Figure 12: Opioids Market, Licensing Agreements by Value ($m), 2005–2012 34
Figure 13: Opioids Market, Co-Development Agreements by Year, 2005–2012 38

Upcoming Reports:

Low Density Polyethylene (LDPE) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
By - Transparency Market Research
Low Density Polyethylene (LDPE) is a thermoplastic polymer of ethylene made by process of free radical polymerization at high pressure. It has density in the range of 0.910g/cc to 0.940g/cc which results in low tensile strength but high ductility. LDPE offers high electrical & chemical resistance and transparency which makes it ideal to use in end industries such as flexible packaging, automotive, construction, green house, tunnels, insulation coax and others.  Rising demand from automotive and construction industry is expected to drive LDPE market. Changing lifestyle...
Poland: currants and gooseberries market
By - Williams and Marshal Strategy
Analysis and dynamics of the economy of Poland; Forecast for the development of the economy of Poland; Analysis and forecast of market volume and dynamics; Volume, dynamics and analysis of domestic production; Characteristics of market structure (by origin, by types of products, etc.); Analysis of price level and dynamics; Volume, dynamics and analysis of imports; Volume, dynamics and analysis of exports; Volume, dynamics and analysis of consumption; Characteristics of the main market participants (manufacturers, importers and exporters); Analysis of the factors, influencing the...
Bio-services Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2012 - 2018
By - Transparency Market Research
Bio-services involve preclinical and clinical researches done by following the standards laid down by regulatory bodies. Clinical research organizations (CRO) segment their researches by contracts, manufacturing, and clinical trials. A clinical trial is a time consuming process, and specifies testing of the new drugs on specific people or for particular diseases. CRO can be divided into captive and independent. The former involves developing and testing of developed drug in-house whereas the latter involves testing of drugs developed by some other organization. ...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Nuclear Development Plans in China Gets Fresh Impetus
Mar 5, 2015  
The nuclear development plans of China got a renewed momentum on Wednesday as State Council gave a nod to build new reactors at the nuclear power plant located near Hongyan River. The unit 5 and 6 of the nuclear plant near Hongyan River, located in the northeastern province of Liaoning got approval for construction from the State Council. The council also mentioned that the construction should...
Indian Telecoms Bid at Spectrum War
Mar 5, 2015  
The Indian government on Wednesday managed to mop up nearly INR 60,000 crore with the spectrum auctions off to a wonderful start. Top bidders included Idea Cellular, Bharti Airtel, and Vodafone India who fought tooth and nail to gain secure airwaves in those areas where their licenses were nearing expiration. Reliance Jio Infocomm made a strenuous attempt to acquire as many data airwaves as...
South Korean Pharmaceutical Companies Extend Business with Saudi Arabia
Mar 5, 2015  
Four South Korean pharmaceutical companies will export their products to Saudi Arabia, including anticancer drugs and antibiotics, for the coming five years, South Korea’s Health Ministry informed this Wednesday, as a result of South Korean President Park Geun-hye's business trip to the Saudi Arabia this week. Ascertaining to the export agreement, representatives of these four Korean...
U.K. Government Slow to Stop Pharma R&D Slump
Mar 4, 2015  
When it comes to turnaround strategies, the focal point of the U.K. government is currently the life sciences industry. Recent data however shows that healthcare companies are spending less and less on research and development processes on drugs in the country. The Office of National Statistics released the data earlier this week. It shows the United Kingdom’s drug production...
Sun Pharma Buys Out GSK Australian Opiates Business
Mar 4, 2015  
Global pharmaceutical giant GSK announced on Tuesday that they had come to an agreement with Sun Pharmaceuticals Industries for the latter to buy out the opiates business in Australia owned by GSK. A joint statement was made by the two pharma top companies. The statement said that the companies’ respective wholly owned subsidiaries had already come to an agreement that was...